# Antibody Treatment for Advanced Celiac Disease

> **NCT01893775** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Celiac Disease
- Celiac Sprue
- Gluten Enteropathy
- Gluten-Sensitive Enteropathy

## Interventions

- **BIOLOGICAL:** Hu-Mik- Beta-1

## Key facts

- **NCT ID:** NCT01893775
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-12
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-20
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893775, "Antibody Treatment for Advanced Celiac Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01893775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*